CD19 and lymphoma: Recent approval of CD19-CAR-T cells for use in patients with certain lymphomas and acute lymphoblastic leukemia by US-American and European regulatory agencies has transformed CAR-T-cell therapy from a mere experimental therapeutic modality to a licensed living drug.